# Restore Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/restore-medical

- Industry: Medical Devices & Equipment
- Headquarters: St. Paul, US
- Website: www.restoremedical.com
- Total disclosed funding: $27M
- Latest round: Series C (Mar 19, 2004)
- Investors on record: 10

## About

Restore Medical, Inc. is dedicated to developing innovative medical devices aimed at improving patient outcomes through advanced healthcare solutions. Their focus on technology enhances care in clinical settings across various demographics.Founded in 1999 in St. Paul, US, Restore Medical, Inc. specializes in medical devices that enhance patient healthcare. The company was acquired by Medtronic in July 2008 for USD 29 mn. Juan Gordo founded the company, and Gilad Marom currently serves as CEO. Restore Medical has participated in 3 funding rounds, with the most recent Trade Sale occurring on May 17, 2006, resulting in a total amount raised of USD 29 mn.Restore Medical specializes in providing innovative solutions within the healthcare sector, focusing on medical devices and technologies designed to enhance patient outcomes. Their core offerings include advanced medical products aimed at addressing specific health challenges faced by patients in clinical settings, catering primarily to healthcare providers, hospitals, and outpatient facilities. Restore Medical's solutions are marketed primarily in North America, with growing interest in international opportunities, particularly in Europe and Asia, reflecting a commitment to expanding their reach within the global medical device market.In 2007, Restore Medical reported revenue of USD 4.10 mn and an EBITDA of USD -13.44 mn. The company generates revenue through direct sales of its medical devices to healthcare institutions and practitioners, primarily utilizing a B2B transaction structure to drive sales through partnerships and direct outreach to medical facilities.Restore Medical, Inc. aims to leverage its recent acquisition by Medtronic to enhance product development and expand into new markets. Following the completion of their Trade Sale in May 2006, the company is focusing on launching new medical devices designed to address emerging health challenges. They are targeting expansion into European and Asian markets by 2025, utilizing the recent funding to support these initiatives and enhance their product offerings.

## Funding rounds

- Series C, Mar 19, 2004, $27M — Focus Ventures, NGEN Partners, DuPont Capital, 3V SourceOne Capital, Bessemer Venture Partners, TWP Private Wealth Management, GE Asset Management, MPM BioImpact, Putnam Investments, Venturi Group

## Investors

- Focus Ventures (https://capitalatlas.ai/funds/focus-ventures) — Series C
- NGEN Partners (https://capitalatlas.ai/funds/ngen-partners) — Series C
- DuPont Capital (https://capitalatlas.ai/funds/dupont-capital) — Series C
- 3V SourceOne Capital (https://capitalatlas.ai/funds/3v-sourceone-capital) — Series C
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series C
- TWP Private Wealth Management (https://capitalatlas.ai/funds/twp-private-wealth-management) — Series C
- GE Asset Management (https://capitalatlas.ai/funds/ge-asset-management) — Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series C
- Putnam Investments — Series C
- Venturi Group (https://capitalatlas.ai/funds/venturi-group) — Series C